|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All |
Recent | 15: Apr | Mar | Feb | Jan | 14: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositionsBelow are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 05/21/2015 > 246 patent applications in 126 patent subcategories.
20150139899 - Neo antibodies for diagnostic imaging of tissue injury: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.... Agent:
20150139900 - Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies: An in vivo method for detecting α-synuclein protofibrils in human tissue comprises administering an antibody or fragment thereof to a human, wherein the antibody or fragment thereof is labelled with a detectable label, and detecting a complex formed between the antibody or fragment thereof and α-synuclein protofibrils in the human... Agent:
20150139901 - Radioactive rhodium complexes, preparation methods and uses thereof: The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.... Agent: Universite D' Angers
20150139902 - Purification of [18f] - fluciclatide: The present invention relates to a method of purification of [18F]-fluciclatide via solid phase extraction (SPE). The method is amenable to automation, and is suitable for use in conjunction with automated synthesizer apparatus—especially cassette-based synthesizers. Also provided are cassettes for carrying out the purification method.... Agent: Ge Healthcare Limited
20150139903 - Phosphodiesterase 1-targeting tracers and methods: Tracers targeting phosphodiesterase1 for use in gamma radiation detection-based diagnostic techniques, particularly gamma-emitter labeled tracers for SPECT and positron emitter-labeled compositions for PET are disclosed. Radio-labeled multiple novel scaffolds as PDE1 inhibitors such as substituted pyrazolo-pyrimidin-4-one derivatives, biomarkers for phosphodiesterase 1 [PDE1) in vivo, methods for developing novel therapies for... Agent:
20150139907 - Calcium-binding agents induce hair growth and/or nail growth: This invention provides novel methods for inducing hair growth and/or inhibiting hair loss and/or inducing nail growth in a mammal. In various embodiments the methods involve administering, e.g., to a mammal in need thereof, a calcium-binding peptide and/or peptide-like moiety in an amount sufficient to induce hair growth and/or to... Agent:
20150139904 - Dendrimer conjugates for coating cells: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.... Agent: University Of Miami
20150139906 - Surface-modified nanoparticles for intracellular delivery of therapeutic agents and compositions for making same: Surface-modified polymeric nanoparticles (NPs), compositions for making them, and their use in drug delivery are disclosed.... Agent:
20150139905 - Targeted therapeutics: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a... Agent:
20150139908 - Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method: The invention provides a labeling composition for an intraocular tissue of a living individual, which specifically labels the intraocular tissue without need of an invasive operation such as exposure of an ocular tissue or injection of a staining agent into the ocular tissue or a nerve tissue linking to the... Agent:
20150139909 - Compositions and methods for treating or preventing osteoarthritis: The present invention relates to the field of osteoarthritis. More specifically, the present invention provides compositions and methods useful for treating or preventing osteoarthritis. In one embodiment, a method for treating or preventing osteoarthritis in a patient comprises the step of administering to the patient a therapeutically effective amount of... Agent:
20150139910 - Fluorecscent, spherical sophorolipid mesostructures for imaging and therapeutic applications: UV-Laser-synthesized, fluorescent, spherical and magnetic nanoparticles are loaded Sophorolipid mesostructures useful for bio-imaging and therapeutic applications.... Agent:
20150139914 - Contrast-enhancing agent for nuclear magnetic resonance imaging comprising melanin nanoparticles stably dispersed in water: The present invention relates to a contrast agent for nuclear magnetic resonance imaging, and more particularly, to a contrast agent for nuclear magnetic resonance imaging containing melanin nanoparticles having a uniform shape and size, thereby providing good dispersibility in water, no cell toxicity, and a long retention time in vivo.... Agent:
20150139911 - Prevention of myocardial infarction induced ventricular expansion and remodeling: A method for direct therapeutic treatment of myocardial tissue in a localized region of a heart having a pathological condition. The method includes identifying a target region of the myocardium and applying material directly and substantially only to at least a portion of the myocardial tissue of the target region.... Agent: Cormend Technologies, LLC
20150139912 - Ct contrast medium for detecting thrombus, comprising fibrin-targeted peptide sequence-conjugated glycol chitosan-gold nanoparticles: The present invention relates to a CT contrast agent for detecting a thrombus, comprising fibrin-targeted peptide sequence-conjugated glycol chitosan-gold nanoparticles. The CT contrast agent for detecting a thrombus according to an embodiment of the present invention may allow rapid and repeated acquisition of CT image information related to the size... Agent:
20150139913 - Medical use of particles of titanium and/or titanium oxide: The present invention describes particles of titanium, titanium alloy, at least one type of titanium oxide or a combination thereof, wherein at least a substantial amount of the particles are of micrometer-millimeter size and are non-spherical, for use as an X-ray contrast agent. The irregular shapes and/or internal pores and... Agent: Migrata U.k. Limited
20150139916 - Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.... Agent: Chiesi Farmaceutici S.p.a.
20150139915 - Methods to decrease susceptibility to asthmatic bronchoconstriction: Methods and compositions are described for reducing airway reactivity and the susceptibility to asthmatic bronchoconstriction that involve increasing sphingolipid content in airways and lungs of a mammalian subject.... Agent:
20150139917 - Aerosol device based on sebum-absorbing powder and a particular water-insoluble mineral compound: The invention relates to an aerosol device which contains a cosmetic composition comprising: (i) one or more sebum-absorbing powders with a sebum uptake of greater than or equal to 35 ml/100 g, (ii) a water-insoluble mineral compound which is calcium carbonate, (iii) one or more C2-4 monoalcohols, and (iv) one... Agent:
20150139918 - Mixtures having improved cooling effect: A mixtures which contain (a) at least one phenylalkenal of formula (I) wherein R1 and R2 independently represent hydrogen, a methyl or phenyl group, R3 represents hydrogen, a phenyl group, alkenyl group or a linear or branched alkyl group with 1 to 5 carbon atoms, and the broken double lines... Agent:
20150139919 - Hydrogel compositions for tooth whitening: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding to the hydrophilic polymer, and a whitening agent, preferably a peroxide. The composition finds utility as a tooth whitening composition and is applied to... Agent:
20150139920 - Oil-based compositions for enhancing oral health and general wellness in humans: An oil-based composition comprises a glyceride of medium-chain fatty acids, at least one essential oil selected from the group consisting of cinnamon oil, oregano oil, avocado oil, coconut oil and apricot oil, and optionally cinnamon bark. The medium-chain fatty acid comprises about 6 to 12 carbon atoms. The oil-based composition... Agent:
20150139921 - Compositions containing titanate silicone networks: The invention relates generally to gels or viscous fluids formed by the coordination of certain amino-functionalized siloxanes with titanates and the use of the same in cosmetic compositions, including for providing long-wearing, comfortable films on a keratinous surface (e.g., lips). The gels or viscous fluids may exhibit unique rheological properties,... Agent:
20150139923 - Cosmetic compostion: A cosmetic composition comprises a) an N-acyl amino acid compound selected from the group consisting of N-acyl amino acid, its isomers, its salts, derivatives thereof, and mixtures thereof, and b) hexyldecanol.... Agent:
20150139922 - Extracts of darlingtonia californica: The present invention relates to an extract from plant parts of Darlingtonia californica, to a process for the preparation thereof, to the use of the extract in cosmetic or dermatological preparations and as self-tanning agent, and to preparations comprising an extract from plant parts of Darlingtonia californica and the preparation... Agent: Merck Patent Gmbh
20150139924 - Fast curing cosmetic compositions for tack free surface photocuring of radically polymerizable resins with uv-led: Disclosed herein are cosmetic compositions comprising (a) at least one ethylenically unsaturated polymerizable compound and (b) at least one photoinitiator system comprising at least one photoinitiator having at least one absorption wavelength greater than about 350 nm. Also disclosed herein are methods of making up and/or enhancing the appearance of... Agent: L'oreal
20150139925 - Cosmetic composition for keratin fibers: The present invention mainly relates to a cosmetic composition for keratin fibers, comprising: (a) at least one fatty material; (b) at least one nonionic surfactant with an HLB of 10 or less; (c) at least one nonionic surfactant with an HLB of more than 10; and (d) water wherein the... Agent: L'oreal
20150139927 - Antiperspirants and deodorants: Products and methods are disclosed for reducing the production of unwanted odors on the human body.... Agent:
20150139926 - Grip enhancing composition and method of use: A composition/formula for enhancing the grip of certain athletes and professionals to hold onto or otherwise “stick” on an object like a sports or tool handle or exercise mat/pad. The composition consists of: a magnesium carbonate base to which are added a natural gum rosin, isopropyl alcohol, hydroxyl ethyl cellulose... Agent:
20150139928 - Drying, anti-smear, and anti-odor agent for spray tanning: In some example embodiments, there is provided a method for sunless tanning. The method may include applying a sunless tanning solution to the skin and applying, during a drying stage of the sunless tanning solution, a powder to at least dry the tanning solution. Related compounds and methods may also... Agent:
20150139929 - Personal care composition and method of use thereof: A solid personal care composition comprising at least 60 wt % of one or more solid surfactants of which at least 10 wt % comprises one or more compounds of formula (I) wherein R1 represents a C4-36 substituted or unsubstituted hydrocarbyl group; each of R2, R3, R4 and R5 independently... Agent:
20150139931 - Organopolysiloxane graft polymer: The present invention relates to a organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived polymer segment as a side chain thereof, in which the unsaturated monomer-derived polymer segment contains a repeating unit derived from N,N-dimethyl acrylamide in an amount of not less... Agent: Kao Corporation
20150139930 - Personal care compositions including narrow molecular weight range copolymers: Personal Care compositions including one or more narrow molecular weight range copolymers have certain weight average molecular weights that provide low viscosity profiles and improved spray performance while also providing improved shampoo removability, hold, stiffness and feel compared to un-fractionated copolymers.... Agent: Akzo Nobel Chemicals International B.v.
20150139932 - Ophthalmic compositions comprising povidone-iodine: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well... Agent:
20150139933 - Method for preparation of poly(alpha-lipoic acid) polymers: A method for the polymerization of α-lipoic acid and α-lipoic acid derivatives includes preparing an α-lipoic formulation, exposing the α-lipoic formulation to an aqueous phase and a gaseous phase at a gas/water interface, and allowing the α-lipoic formulation to polymerize at the gas/water interface to form a poly(α-lipoic acid) polymer.... Agent:
20150139934 - Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof: A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick... Agent:
20150139935 - Sleep apnea treatment: Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate.... Agent: The Regents Of The University Of Michigan
20150139936 - Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics: Provided are methods and compositions for clinical treatment of advanced HER2 positive solid tumors cancer using combination therapies comprising bispecific anti-ErbB2/anti-ErbB3 antibodies.... Agent: Merrimack Pharmaceuticals, Inc.
20150139938 - Methods and compositions for improving pial collateral circulation and treating blood clotting disorders: The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix... Agent: Ohio State Innovation Foundation
20150139937 - Methods and compositions for inhibiting diseases of the central nervous system: Methods and compositions for treating central nervous system diseases and disorders are disclosed.... Agent:
20150139939 - Cancer stem cell targeted cancer vaccines: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the... Agent: Stemline Therapeutics, Inc.
20150139943 - Chimeric receptors and uses thereof in immune therapy: Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig) (e.g., an extracellular ligand-binding domain of F158 FCGR3A or V158 FCGR3A variant); a transmembrane domain (e.g., a transmembrane domain of CD8α); at least one co-stimulatory signaling domain (e.g.,... Agent: St. Jude Children's Research Hospital
20150139941 - Combined therapy and prophylaxis for genital tract infections: Provided is a method for treating and reducing the recurrence of genital tract infections such as gonococcal infections. The method comprises local application of IL-12 incorporated in polymeric microspheres. The invention relates to compositions comprising IL-12 and methods for using such compositions for treatment of genital tract infections. Infections that... Agent: The Research Foundation For The The State University Of New York
20150139945 - Compositions and methods for immunomodulation in an organism: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex... Agent: University Of Connecticut
20150139942 - Method for tretaing a gd2 positive cancer: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.... Agent: Apeiron Biologics Ag
20150139944 - Separatone-based protein expression and purification platform: Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast,... Agent:
20150139940 - Stress-regulated prokaryotic expression cassettes: o
20150139946 - Detecting mutations in disease over time: Provided is a method for monitoring a gene mutation associated with a cancer in a patient over time. Also provided is a method of selecting and/or applying treatment or therapy for a subject.... Agent:
20150139947 - Immunoglobulin chimeric monomer-dimer hybrids: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of... Agent: Biogen Idec Hemophilia Inc.
20150139948 - Modulators of pharmacokinetic properties of therapeutics: e
20150139950 - Alisporivir to treat hepatitis c virus infection: The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection.... Agent: Novartis Ag
20150139949 - Anti-viral combination therapy: The present invention provides methods and compounds for treating viral infections using combinations modulators of an HCV-associated component and modulators of host cell enzymes. The present invention also provides methods and compounds for treating viral infections using combinations of modulators of host cell enzymes and other agents that work, at... Agent:
20150139951 - Engineered antibody-interferon mutant fusion molecules: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver... Agent:
20150139953 - Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.... Agent:
20150139952 - Methods, compositions, cells, and kits for treating ischemic injury: The methods, compositions, cells and kits described herein are based on the discovery that stem cells, when injected into ischemic tissue of mammals, can be protected by preconditioning of the ischemic tissue with hypoxia-regulated human VEGF and human IGF-1. Methods, compositions, cells and kits for treating tissue injured by ischemia... Agent:
20150139954 - Recombinant herpes virus and pharmaceutical composition containing recombinant herpes virus: A recombinant herpes virus showing high antitumor activity is provided. In particular, a recombinant herpes simplex virus that expresses an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus is provided.... Agent: The University Of Tokyo
20150139967 - Method of treating ischemic disorders: Provided are methods of treating ischemic disorders in a subject includes administering stromal cell derived factor-1 (SDF-1) to ischemic tissue of the subject.... Agent:
20150139966 - Methods of using hcn genes to treat cardiac arrhythmias: The subject invention is directed to methods of treating cardiac pacing dysfunction by administering HCN genes, alone or in combination with other genes.... Agent:
20150139955 - Agent for promoting proliferation of bifidobacteria: A peptide dimer comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and a peptide consisting of any one of the amino acid sequences of SEQ ID NOS: 2 to 4, wherein the peptide consisting of the amino acid sequence of SEQ ID NO: 1... Agent: Morinaga Milk Industry Co., Ltd.
20150139959 - Bacterial isolate, methods of isolating bacterial isolates and methods for detoxification of trichothecene mycotoxins: The invention provides a bacterial isolate defined by accession number 040408-1 filed with the International Depository Authority of Canada. The bacteria are capable of detoxifying trichothecene mycotoxins. Also provided are compositions including the bacteria and methods of preventing or treating food or foodstuffs that are contaminated or susceptible to contamination... Agent:
20150139956 - Compositions which regulate the epithelial brush border na+/h+ exchanger nhe3 and their methods of use in gastrointestinal disease: A synthetic peptide modeled on the IRCX binding area of NHE3, is a competitive inhibitor of the IRCX and both stimulates basal NHE3 activity and prevents elevated Ca2+ and cAMP inhibition of NHE3. Methods of its preparation and use in the prevention and/or treatment of gastrointestinal disease, such as diarrhea... Agent:
20150139958 - Feed composition and production method for same: Provided are a feed composition, which can be stored for a long time and is easily produced and adjustable in components, and which can increase the body weight and reduce a feed conversion ratio of farm animals to which the feed composition is fed, and a production method for the... Agent:
20150139957 - Growth enhancing additive from pomegranate plant for poultry feed: A method for enhancing the growth, increasing feed utilization and reducing mortality in poultry (such as chickens and turkeys) by adding a pomegranate-derived additive to their feed. Pomegranate-derived additive and its use for enhancing growth of poultry without growth-promoting antibiotics.... Agent: Ganir (1992) Ltd
20150139968 - Probiotic composition for treating picornavirus infection and its use thereof: The present invention relates to a composition used for treating picornavirus infection comprising at least one of the following bacterial strains: Lactobacillus paracasei GMNL-33 with the deposition numbers of CCTCC M 206133, Lactobacillus reuteri GMNL-89 with the deposition numbers of CCTCC M 207154 and Lactobacillus casei GMNL-277 with the deposition... Agent: Genmont Biotech Inc.
20150139969 - Use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli: The present disclosure relates to the use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli bacteria, the thiosulfate being in a quantity of at least 100 mg for 107 to 1010 CFU of lactobacilli. The disclosure also relates to a pharmaceutical composition including at least 100 mg of thiosulfate... Agent: Probionov
20150139970 - Novel lactic acid bacterium: This invention provides lactic acid bacteria that have one or more effects selected from among fatigue-ameliorating effect, blood circulation-improving effect, stool odor-reducing effect, and growth-promoting effect and that can be used with high safety. This invention further provides a pharmaceutical preparation comprising, as an active ingredient, lactic acid bacteria that... Agent: Kaneka Corporation
20150139964 - Body fluid expanders comprising n-substituted aminosulfonic acid buffers: A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The solutions are useful for the manufacture of medicaments and blood volume expanders, for... Agent:
20150139963 - Isolated populations of renal stem cells and methods of isolating and using same: Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.... Agent:
20150139965 - Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
20150139961 - Reprogramming blood cells to pluripotent and multipotent stem cells: The present invention is based on the seminal discovery that cord blood (CB) and adult bone marrow (BM) CD34+ cells can be reprogrammed to early stem cells. The invention provides the reprogramming of CB and adult bone marrow (BM) CD34+ cells from subjects without any pre-treatment. Provided are methods for... Agent:
20150139960 - Skin printing and auto-grafting: An apparatus and method for the production of substitute skin that advantageously reduces the amount of donor dermal cells needed from non-wound areas of a patient having a wound to be auto-grafted is reduced by using all of the harvested skin cells. A 3D printer is used to construct a... Agent:
20150139971 - Method for preparing regulatory dendritic cells: An object of the present invention is to establish a method that enables safe and convenient large-scale preparation of regulatory dendritic cells. The present invention provides a method for preparing regulatory dendritic cells, which comprises culturing cells that can be induced to result in regulatory dendritic cells in the presence... Agent: National University Corporation Hokkaido University
20150139972 - Micronutrient formulation for concussive head injuries: A concussive injury micronutrient formulation is provided and the formulation comprises vitamin A, vitamin E, natural mixed carotenoids, vitamin C, vitamin D, coenzyme Q10, alpha-lipoic acid, N-acetyl cysteine, acetyl L-carnitine (fumarate), vitamin B, folic acid, calcium, magnesium, selenium, chromium, biotin, zinc, and omega-3 fatty acids.... Agent:
20150139973 - Ophthalmological vehicle system for drugs, ophthalmological kit and also use of an ophthalmological composition: The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue... Agent:
20150139974 - Rca locus analysis to assess susceptibility to amd and mpgnii: The invention relates to gene polymorphisms and genetic profiles associated with an elevated or a reduced risk of alternative complement cascade deregulation disease such as AMD and/or MPGNII. The invention provides methods and reagents for determination of risk, diagnosis and treatment of such diseases. In an embodiment, the present invention... Agent:
20150139975 - Recombinant factor h and variants and conjugates thereof: The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.... Agent:
20150139976 - Novel insecticidal chitinase protein its encoding nucleotide and application thereof: A novel insecticidal chitinase protein from fern Tectaria sp., a process for preparation of the insecticidal protein and nucleic acid sequence encoding for said insecticidal protein and its application for insect control purposes.... Agent:
20150139977 - Xylanases, nucleic acids encoding them and methods for making and using them: The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal β-1,4-xylosidic linkages or endo-β-1,4-glucanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of... Agent:
20150139978 - Novel monascuspurpurones, preparation process thereof, and uses of the monascuspurpurones: or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPARγ and/or C/EBPα, for lowering blood glucose, for preventing and/or treating... Agent:
20150139984 - Active protease-resistant antibody fc mutants: The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with FcγR receptors except with FcγRI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them.... Agent:
20150139982 - Anti-siglec-15 antibodies: Antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. These antibodies or antigen binding fragments may have the ability of inhibiting differentiation of osteoclasts and/or the ability of inhibiting the bone resorption activity of osteoclasts. Compositions and cells expressing anti-Siglec-15 antibodies or antigen binding fragments are... Agent: Alethia Biotherapeutics Inc.
20150139989 - Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell... Agent: Fundacio Privada Institucio Catalana De Recerca I Estudis Avancats (icrea)
20150139980 - Detectors of serum biomarkers for predicting ovarian cancer recurrence: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the... Agent:
20150139981 - Enzymatic modification of anti-aqp4 autoantibody for modulating neuromyelitis optica: Provided herein is a method of treating neuromyelitis optica (NMO) in an animal or human subject comprising administering to the subject a composition comprising a therapeutically effective amount of an Fc region modified anli-AQP4 antibody, thereby treating the NMO in the subject, in some embodiments, the Fc region modified anti-AQP4... Agent: The Regents Of The University Of California
20150139988 - Glycoengineered binding protein compositions: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.... Agent: Abbvie, Inc.
20150139990 - Human monoclonal antibody: The invention provides a method for the prophylaxis, improvement, or treatment of inflammatory bowel disease, multiple sclerosis, and psoriasis by administering to a subject an effective amount of an isolated anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of amino acid numbers... Agent:
20150139986 - Ilt3 binding molecules and uses therefor: e
20150139979 - Methods of treating a disease or disorder associated with bruton's tyrosine kinase: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.... Agent: Celgene Avilomics Research, Inc.
20150139985 - Novel compositions and methods for treating ige-mediated disorders: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.... Agent:
20150139987 - Treatment of homozygous familial hypercholesterolemia: Treatment of homozygous familial hypercholesterolemia by administration of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof, optionally in combination with an MTP inhibitor, an apoB-100 synthesis inhibitor, or a PCSK9 inhibitor.... Agent: Cymabay Therapeutics, Inc.
20150139983 - Use of blocking agents of bone morphogenic protein (bmp) signalling for the treatment of neuroinflammatory and neurodegenerative diseases: The invention provides pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of Bone Morphogenic Protein (BMP) signaling. The invention further provides methods of treatment of neuroinflammatory or neurodegenerative diseases comprising administering to a patient in need thereof the... Agent:
20150139992 - Baff receptor (bcma), an immunoregulatory agent: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.... Agent: Biogen Idec Ma Inc.
20150139994 - Compositions and methods for preventing allogeneic immune rejection: The present invention provides methods for preventing the allogeneic immune rejection of allogeneic cells, such as cells derived from human Embryonic Stem Cells (hESCs), without suppressing the entire immune system. Also provided a vector containing a CTLA4-Ig and PD-L1 expression cassette, and compositions containing a CTLA4-Ig and PD-L1 for use... Agent: The Regents Of The University Of California
20150139991 - Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain: The invention relates to the design of trimeric polypeptide complexes using polypeptide structural elements derived from the collagen XVIII protein, and their use in diagnostic and therapeutic systems in vivo and in vitro. The invention also relates to nucleic acids and vectors useful for producing said trimeric complexes.... Agent: Leadartis, S.l.
20150139993 - Hemojuvelin fusion proteins and uses thereof: The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof.... Agent:
20150139995 - Methods and compositions for modulating toso activity: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.... Agent:
20150139997 - Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof: Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.... Agent: International - Drug - Development - Biotech
20150139996 - Methods and means for the production of ig-like molecules: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.... Agent:
20150139998 - Novel cell wall polymers of enterococcus faecalis and uses thereof: The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.... Agent:
20150140003 - Anti-alpha-synuclein antibodies and methods of use: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.... Agent:
20150139999 - Interferon antagonists, antibodies thereto, and associated methods of use: Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists... Agent:
20150140001 - Novel antibody specific for clec14a and uses thereof: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clecl4a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition... Agent: Scripps Korea Antibody Institute
20150140000 - Tlr3 binding agents: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.... Agent:
20150140002 - Use of a pcsk9 inhibitor to treat hyperlipidemia: The present invention provides methods for treating hyperlipidemia in patients who are not on statin therapy. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred... Agent:
20150140004 - Hydroxycholesterol immunoassay: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol,... Agent: Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.
20150140006 - Low acidic species compositions and methods for producing and using the same: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNFα... Agent:
20150140005 - Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory... Agent:
20150140007 - Pharmaceutical composition for treating and/or preventing type i diabetes and application thereof: The present invention provides a composition for treating and/or preventing type I diabetes and an application thereof. The active ingredient of the composition is 1.) or 2.) or 3.), as follows: 1.) a mixture of a type I diabetes protein antigen and an immunosuppressor, 2.) a mixture of a type... Agent:
20150140009 - Compositions and methods for the treatment of radiation exposure: The invention provides methods for the treatment of radiation exposure featuring agents that interfere with the expression, production, release, accumulation, or activity of a TNFα, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES receptor; or a TNF-α, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES peptide... Agent:
20150140008 - Uses of cxcl17, a novel chemokine marker of human lung and gastrointestinal disease: A method of treating a disease associated with increased levels of chemokine CXCL17. The method includes administering to a subject in need of such treatment a therapeutically effective amount of a substance that lowers the level of CXCL17 activity. The substance can be a CXCL17 antibody, or an antisense compound... Agent: The Regents Of The University Of California
20150140011 - Il-6 binding molecules: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its... Agent: Argen-x B.v.
20150140010 - Methods for diagnosing and treating focal segmental glomerulosclerosis: The present invention relates to methods for diagnosing and treating focal segmental glomerulosclerosis. More particularly, the present invention relates to a method for determining whether a subject is at risk of having or developing a focal segmental glomerulosclerosis (FSGS) comprising the step consisting of determining the level of calcium/calmodulin-dependent serine... Agent: Assistance Publique-hopitaux De Paris
20150140013 - Modulation of asymmetric proliferation: Provided herein are methods and compositions related to modulation of the rate of asymmetric proliferation of cancer cells. In some embodiments, the methods described herein relate to the treatment of cancer, at least in part, via the modulation of the rate of asymmetric proliferation of cancer cells.... Agent: The General Hospital Corporation
20150140012 - Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.... Agent: Nuvo Research Ag
20150140014 - Method of combination therapy using an anti-c-met antibody: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an... Agent: Samsung Electronics Co., Ltd.
20150140015 - Methods and pharmaceutical compositions for the treatment of pancreatic cancer: The present invention relates to methods and pharmaceutical compositions for the treatment of pancreatic cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of pancreatic cancer in a subject in need thereof.... Agent:
20150140016 - Molecular determinants of myeloma bone disease and uses thereof: The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods for treating multiple myeloma, for restoring osteoprotegerin (OPG) expression in a cell, for inhibiting receptor activator of nuclear factor... Agent: Board Of Trustees Of The University Of Arkansas
20150140017 - Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer: The present invention relates to predictors of a cancer patient's responsiveness to immunotherapy for cancer.... Agent:
20150140018 - Anti-cxadr antibody: An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells)... Agent: Microbial Chemistry Research Foundation
20150140019 - Compositions and methods for regulating car t cells: The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of... Agent:
20150140020 - Pharmaceutical composition for treating adverse reactions due to administration of spiegelmers: The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for trating undesired physiological adverse reactions due to the administration of a therapeautic modecule containing the L-RNA.... Agent:
20150140021 - Therapeutic biologic for treatment of hepatocellular carcinoma: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods... Agent:
20150140022 - Novel photoimmunoconjugates for use in photodynamic therapy: e
20150140023 - Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers: The monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of the antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, the antibody or the fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and... Agent:
20150140024 - Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung
20150140025 - Herpes simplex virus vaccine: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell... Agent:
20150140026 - Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting... Agent: Arne Forsgren Ab
20150140027 - Antigens and vaccines directed against human enteroviruses: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a... Agent:
20150140028 - Recombinant bacterium and uses thereof: The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host... Agent:
20150140029 - Extracts from fusarium oxysporums and use thereof: Disclosed are the action and use of water extracts and polysaccharides from Fusarium oxysporums in immune enhancement, which belong to the field of biological pharmacy. The water extracts and polysaccharides from Fusarium oxysporums have a significant immune enhancement effect, which can promote the proliferation of macrophages, increase the phagocytic ability... Agent: University Of Macau, Av. Padre Tomas Pereira Taipa
20150140030 - Method for refining squalene produced by microalgae: The invention relates to a method for preparing a composition that is very rich in squalene produced by fermentation of micro-organisms. The method is characterised in that it comprises a purification step selected from the group including: supercritical CO2 extraction in a multi-stage counter-current fractionation column with extract reflux, and... Agent:
20150140031 - Weight management systems and related methods: Systems and methods of weight management and compositions or formulations useful therein are disclosed and described.... Agent:
20150140032 - Vaccine: The present invention is based on the finding that microorganisms can be modified so as to express certain factors important in generating or raising host immune responses. In particular, the invention provides modified microorganisms which, when subjected to conditions which would be expected to suppress or reduce the expression, function... Agent:
20150140033 - C. perfringens alpha toxoid vaccine: The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any combination thereof. The present invention further describes methods of using with these vaccines to protect animals against clostridial diseases. The present invention also describes... Agent:
20150140034 - Oil-based adjuvants: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.... Agent:
20150140035 - Autologous biological cancer vaccine: The present disclosure relates to an autologous biological cancer vaccine and to a method for preparing the same. The vaccine of the present application is a biological vaccine obtained from overexpressed proteins in the serum of cancer patients, proteins to which have been added immunological adjuvants such as an attenuated... Agent:
20150140036 - Low, immune enhancing, dose mtor inhibitors and uses thereof: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.... Agent: Novartis Institutes For Biomedical Research, Inc.
20150140037 - Non-replicating bacterial nanoparticle delivery system and methods of use: The present invention provides compositions and methods for the secretion and the translocation of a compound of interest by a bacterial minicell. In certain embodiments, the invention provides a bacterial minicell comprising at least one component of the type III secretion system (T3SS), which provides a safe and efficient system... Agent:
20150140038 - Mycobacterium tuberculosis deltaesx-3 mutants: Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.... Agent: Albert Einstein College Of Medicine Of Yeshiva University
20150140039 - Immunological markers for adjuvant therapy in melanoma: The present invention concerns embodiments for determining whether an individual in need of immunotherapy will be responsive to the immunotherapy. Determination of one or more SNPs in particular genes is predictive of responsiveness to immunotherapy, particularly in individuals that have melanoma, for example. In certain embodiments, the SNPs are in... Agent:
20150140040 - Methods of depositing particles of a substance in a tissue: Provided herein are methods of populating a target tissue of interest of a subject with particles of a substance of interest by precipitation. Example methods include administering a solution to a subject, the solution including the substance of interest and a pharmaceutically acceptable solvent. The substance of interest must be... Agent:
20150140041 - Personalized cancer vaccines and adoptive immune cell therapies: Cancer antigens containing mutations in an expressed gene of cancer cells from a cancer patient are identified. Sequences from cancer cells obtained using a parallel sequencing platform are selected by comparing to the patient's normal genes or to normal genes from an HLA-matched individual. Sequences are further selected by identifying... Agent:
20150140044 - Immunomodulation using placental stem cells: The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.... Agent: Anthrogenesis Corporation
20150140043 - Immunomodulatory methods using notch agonists: The invention relates to materials and methods for regulating immune pathways using NOTCH and NOTCH agonists. In particular, said agonists may be used in methods for sensitizing CD4+ CD25− cells to CD4+ CD25+ cell-mediated immunosuppression, for enhancing the TGF-β response of CD4+ CD25− cells.... Agent:
20150140042 - Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections: The present invention concerns a composition comprising micro particles of polyinosinic-polycytidylic acid (Poly (I:C)) and a carrier polymer selected from starch, alginate, blanose or DPPC (dipalmitoylphosphatidylcholine) for use in preventing and/or treating viral infections of the upper respiratory tract or the common cold and a device, preferably a nasal delivery... Agent:
20150140045 - Anti-bacterial applications of poly-n-acetylglucosamine nanofibers: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.... Agent:
20150140046 - Compounds which inhibit neuronal exocytosis: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and... Agent:
20150140052 - Consumer product compositions comprising organopolysiloxane emulsions: Consumer product compositions providing enhanced hydrophobic benefit agent deposition. The benefit agent is provided as a benefit agent/deposition aid emulsion, where the benefit agent is physically adsorbed to the deposition aid before the emulsion is added to the balance of ingredients.... Agent:
20150140049 - Matt-effect composition comprising hydrophobic aerogel particles and silica particles: The present invention relates to a cosmetic and/or dermatological composition comprising, in a physiologically acceptable medium: a) at least some hydrophobic aerogel particles, b) at least some silicaparticles, c) at least one particle that absorbs sebum, the said composition comprising at least one aqueous phase. The invention also relates to... Agent:
20150140047 - Method for the surface application of chemical compounds to both synthetic and natural fibers and a system for same: The present invention relates to a surface treatment and a method for its application for the introduction of a wide variety of differentiating properties to fibersin sliver form through a surface treatment of said fibers. The system can accommodate chemical processes, sonochemical processes, and acoustic cavitation processes whereby the fibers... Agent: Argaman Technologies Ltd.
20150140051 - Microalgae-derived compositions for improving the health and appearance of skin: Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health... Agent:
20150140050 - Process for producing microcapsules: The application describes a process for producing microcapsules which contain a shell made of polyurea and which surround in their interior a fragrance oil core, where the shell is obtained by the reaction of two structurally different diisocyanates in emulsion form.... Agent:
20150140048 - Use of n-methyl-n-acylglucamines as solubilizers: The invention relates to the use of N-methyl-N-C8-C14-acylglucamines as solubilizers in cosmetic preparations. The invention further relates to clear lotions for the preparation of wet wipes, comprising a) 0.1 to 5.0 wt.-% of the N-methyl-N—C8-C14-acylglucamines, b) 0.05 to 5% of one or more water-insoluble or only partially water-soluble anti-microbial agents,... Agent: Clariant Finance (bvi) Limited
20150140053 - Pesticidal composition in the form of aqueous emulsion: A pesticidal composition in the form of an aqueous emulsion contains: (a) an agriculturally active ingredient in which a retention rate is 50% or more after irradiation with xenon light (290 nm cutoff) at an intensity of 0.68 W/m2 at 340 nm for 8 hours, and a retention rate is... Agent:
20150140055 - Biocompatible polyelectrolyte complexes and methods of use: An article comprising a polyelectrolyte complex comprising an interpenetrating network of at least one predominantly positively charged polyelectrolyte polymer and at least one predominantly negatively charged polyelectrolyte polymer, the polyelectrolyte complex further comprising a plurality of closed-shell pores, the plurality of pores having at least one average transverse dimension between... Agent:
20150140054 - Scent/fragrance sampling card and method of manufacture: A scent delivery system in the form of a scent sampling card in which a fragrance/oil of a scented nature is encapsulated in the form of microscopic beads or scent of scented oil encased in a gelatinous or plastic cell wall, the encapsulation protects the microscopic beads and the scent... Agent:
20150140056 - Highly wettable, water dispersible, granules including two pesticides: The present disclosure relates to water dispersible granular pesticide compositions, and methods of making and using the compositions. The pesticide compositions include an inner layer including a first pesticide coated on to a substrate, and an outer layer comprising a second pesticide coated on the inner layer. The outer layer... Agent:
20150140057 - Porated cartilage products: This invention provides porated cartilage products, methods of producing porated cartilage products, and methods of treating subjects by administering cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and... Agent:
20150140060 - Compositions and methods for promoting wound healing and tissue regeneration: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.... Agent:
20150140059 - Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis: This invention relates, e.g., to a synthetic compound, Oxy149, having the structure (Formula I) or a bioactive or pharmaceutical composition comprising Oxy149 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders,... Agent:
20150140058 - Skin printing and auto-grafting: A holey substrate now is used for constructing a graft product, such as building an auto-graft by 3D printing of living cells. When the autograft built atop the holey substrate is implanted, blood vessels and other patient tissues can grow through the holes.... Agent:
20150140061 - Coated stent comprising an hmg-coa reductase inhibitor: Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been... Agent:
20150140062 - Methods of treatment of ocular conditions with a sustained drug delivery implant: Intraocular implants may include a corticosteroid and a biodegradable polymer associated with the corticosteroid to facilitate the release of the corticosteroid into an eye for a period of time. In some embodiments, ocular conditions, such as diabetic macular edema can be treated through administration of an intraocular implant including a... Agent:
20150140063 - Hydrophobic ceragenin compounds and devices incorporating same: A hydrophobic cationic steroidal anti-microbial (ceragenin) compound forms an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face. The hydrophobic CSA also includes a hydrophobic substituent that gives the ceragenin compound a C Log P value of at least 6.0, 6.25, 6.5, 7.5, 8.5, or 10.... Agent: Brigham Young University
20150140064 - Nanoscale collagen particles and membranes: Nano scale collagen particles can be obtained from an embrittling and attrition process that reduces the size of collagen particles to the nano scale. These nano scale collagen particles have many favorable properties such as providing beneficial and enhanced properties for cell seeding and wound healing. The nano scale collagen... Agent: Empire Technology Development LLC
20150140072 - Aminoacyl trna synthetases for modulating inflammation: Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.... Agent:
20150140066 - Carrier for intracellular delivery of functional protein: A liposome comprising a lipid covalently bonded with a polyarginine peptide consisting of 4 to 20 continuous arginine residues and a lipid covalently bonded with a GALA peptide consisting of the amino acid sequence of SEQ ID NO: 1 and/or an R-GALA peptide consisting of the amino acid sequence of... Agent:
20150140074 - Cochleates made with soy phosphatidylserine: Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.... Agent:
20150140075 - Compositions and methods for treatment: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.
20150140076 - Compositions and methods for treatment: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.
20150140077 - Compositions and methods for treatment: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.
20150140078 - Compositions and methods for treatment: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.
20150140079 - Compositions and methods for treatment: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.
20150140080 - Compositions and methods for treatment: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.
20150140081 - Compositions and methods for treatment: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.
20150140082 - Compositions and methods for treatment: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.
20150140069 - Delivery of nucleic acid-like compounds: Provided herein is a process for preparing a microparticulate complex of a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible organic solvent. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component, and... Agent:
20150140073 - Heparosan-multimolecular assembly drug delivery compositions and methods of making and using same: Drug delivery compositions are disclosed that include multimolecular assemblies that have heparosan polymer(s) attached thereto and therapeutic(s) (and/or potential therapeutic(s)) entrapped, carried, or otherwise bound in the multimolecular assemblies. Methods for producing and using the drug delivery compositions are also disclosed.... Agent:
20150140068 - Immunogenic compositions and uses thereof: This invention generally relates to immunogenic compositions that comprise an HIV RNA component and a HIV polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms—a first epitope from human immunodeficiency virus (HIV), in RNA-coded form; and a second epitope from HIV, in polypeptide form—are effective in inducing... Agent:
20150140071 - Kinase inhibitors: The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.... Agent:
20150140070 - Lipid formulations for delivery of messenger rna: e
20150140065 - Method for inducing an immune response and formulations thereof: The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of influenza virus and other infectious diseases. Compositions containing the same, methods for producing the same, and methods... Agent: Cel-sci Corporation
20150140067 - Therapeutic micro rna targets in chronic pulmonary diseases: The present invention relates to the identification of microRNAs of the miR-148 family that are involved in the pathogenesis of chronic pulmonary diseases. The present invention relates to micro RNA of the miR-148 family selected from miR-148a, miR-148b and miR-152 for use in the diagnosis, prognosis, prevention and/or therapy of... Agent:
20150140083 - Pharmaceutical formulation containing gelling agent: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Agent: The P.f. Laboratories, Inc.
20150140084 - Acid resistant banding solution for two piece hard capsules: The present disclosure relates to acid resistant banding solutions for two piece hard capsules, and methods of making the same. The present disclosure also relates, in part, to a method for banding such capsules which provides an acid resistant seal between the capsule parts and achieves an increased acid resistance... Agent: Capsugel Belgium Nv
20150140085 - Formulations comprising ibrutinib: Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.... Agent: Principia Biopharma Inc.
20150140087 - Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists: Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release... Agent:
20150140086 - Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms arc useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing... Agent:
20150140088 - Spirosteroid systems acting as neuroprotective and anti-inflammatory agents: The present invention relates to the fields of chemistry and pharmacy and, in particular, to the production of novel molecular entities: esterane derivatives fused with spirostanes rings, acting upon the Central Nervous Systems (CNS). From diosgenin, a naturally occurring sapogenin, with some subsequent transformations thereof, spirosteroid derivatives of the I-IV... Agent:
20150140089 - Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity: The present invention relates to a novel formulation of sustained-release Nifurtimox with enhanced activity while having low toxicity. The formulation can improve patient compliance by reducing the frequency of administering the drug.... Agent:
20150140090 - Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation: A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain,... Agent:
20150140092 - Coated drug delivery formulations: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present... Agent:
20150140091 - Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose: A solid dispersion comprising at least one active ingredient in at least one hydroxyalkyl methylcellulose having a DS of from 1.0 to 2.7 and an MS of from 0.40 to 1.30, wherein DS is the degree of substitution of methoxyl groups and MS is the molar substitution of hydroxyalkoxyl groups,... Agent: Dow Global Technologies LLC
20150140093 - Nanoclusters compositions and methods: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of... Agent:
20150140094 - Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such... Agent: Vertex Pharmaceuticals Incorporated
20150140095 - Once-a-day oxycodone formulations: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.... Agent:
20150140098 - Animal feed comprising grain and agaricus blazei extract and use of the feed material: The invention relates to the use of feed material comprising grain and Agaricus Blazei, comprising the Agaricus species in an amount between 10 to 50% by weight on dry matter, and the feed material having a moisture content of less than 10% (relative to dry matter), for administration to chicken... Agent: Ssipfeed B.v.
20150140096 - Composition and method of preparation of bone allograft from endosteal portion of bone and isolated bone periosteum: Particulate bone and structural bone, more specifically decalcified bone from endosteum having osteoinductive capacity and methods for their isolation and production are provided, more specifically, decalcified bone preparations derived from endosteal layer of bone are provided. Compositions formulated with material from endosteal layer of bone are provided along with preparation... Agent: Vivex Biomedical Inc.
20150140097 - Crystalline microspheres and the process for manufacturing the same: The present invention relates to microspheres and compositions comprising a plurality of microspheres, wherein the microspheres are perfectly spherical and have a moisture content less than 1%, and the method of manufacturing the same. The present invention is useful in the manufacture of sustained and modified release active pharmaceutical ingredient... Agent: Spi Pharma, Inc.
20150140105 - Free flowing, frozen compositions comprising a therapeutic agent: Disclosed are frozen, free-flowing compositions that may contain one or more therapeutic agents and at least one flavoring agent, such compositions being useful for the delivery of an effective amount of a therapeutic agent to an individual in need thereof. Also disclosed are methods of making and using such compositions.... Agent:
20150140100 - Medical device for treatment of wounds: The present invention describes a medical device comprising a set of particles of titanium oxide, wherein at least a substantial amount of the particles are of micrometer—millimeter size, and wherein at least 10 wt % of the titanium oxide is in the amorphous form.... Agent:
20150140102 - Method to produce a medicinal product comprising a biologically active protein and the resulting product: The present invention pertains to a method for producing a medicinal product comprising a biologically active protein comprising the steps of providing an aqueous composition comprising a solvent, the biologically active protein and between 20% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, thereby forming at least... Agent:
20150140099 - Novel dosage form and formulation of abediterol: A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a delivered dose of aclidinium equivalent to about 322 micrograms aclidinium free base.... Agent:
20150140101 - Solid oral compositions of silodosin: The present disclosure relates to solid oral compositions of silodosin or its pharmaceutically acceptable salt thereof. More particularly capsule compositions of silodosin with one or more pharmaceutically acceptable excipients and process for their preparation.... Agent:
20150140104 - Therapeutic polymeric nanoparticles and methods of making and using same: Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.... Agent: Astrazeneca Ab
20150140103 - Vaccine: The present invention relates to a nucleic acid for vaccine that has undergone codon optimization for expression in Bombyx mori, a vector comprising the nucleic acid, Bombyx mori comprising the vector, and a method for producing a vaccine in which they are used.... Agent:
20150140106 - Ocular nanoformulation and method of use in angiogenesis-mediated disorders: An ophthalmic formulation that includes nanoparticles. Each nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH), with or without hydrophobic anti-angiogenesis Tyrosine Kinase inhibitors. The SNACH is ionically or covalently bonded to the shell. The shell includes a polymer selected from the group consisting of poly (lactic-co-glycolic acid) (PLGA),... Agent:
20150140107 - Delivery of hydrophobic active agent particles: Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix... Agent:
20150140110 - Compositions of jasmonate compounds and methods of use: The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-κB-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.... Agent:
20150140109 - Docetaxel-based prolonged-release cancer treatment drug: The present invention relates to the field of pharmacology and medicine, specifically to a new generation of anticancer drugs with the cytostatic action based on docetaxel. In the drug composition of the invention docetaxel is included in biodigestible stable nanoparticles. The nanoparticles comprise of docetaxel, PLGA, serum albumin and D-mannitol... Agent: Oy Filana Ltd
20150140108 - Lipidated glycosaminoglycan particles for the delivery of nucleic acids: There are provided compositions comprising lipidated glycosaminoglycan particles, methods for their preparation and uses thereof for the efficient in-vivo and in-vitro delivery of nucleic acids, such as, siRNA molecules.... Agent:
20150140111 - Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof: The invention relates to effervescent pharmaceutical dosage forms including cefdinir as the active agent, and their preparation. The invention also relates to effervescent formulations including ceftibuten and/or its pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof. The invention also relates to pharmaceutical compositions including... Agent:
20150140112 - Composition comprising extract of mixture of undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis: The present invention relates to a composition comprising an extract of a mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of Undaria pinnatifida sporophylls and the cell... Agent:
20150140113 - Gelling agent-based dosage form: The present invention generally relates to dosage forms for oral administration including one or more gelling agents. In particular, the present invention is directed to gelling agent-based dosage forms that are easily administered and taken, or swallowed. The present invention is also directed to gelling agent-based dosage forms that exhibit... Agent: Particle Dynamics International, LLC
20150140114 - Skin treatment protocol utilizing amniotic solution: A skin treatment method, including: performing a skin treatment procedure on the skin of a patient, wherein the skin treatment procedure includes one of a chemical peel procedure, a dermabrasion procedure, a micro-needling procedure, and a laser procedure; and subsequently, applying a preparation including one or more of amniotic fluid... Agent:
20150140116 - Bone implant materials comprising cross-linked bioactive hydrogel matrices: The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight... Agent: Pioneer Surgical Technology, Inc.
20150140115 - Oriental medicine compositions marked as sec 22 and sec 33 for improving children's underweight, low growth and depressed respiratory organ: The present invention relates to oriental medicine compositions marked as SEC 22 and SEC 33 for improving digestive functions and respiratory functions for improving children's underweight, low growth and depressed respiratory organ, an oriental medicine derived therefrom, and methods of preparing them. According to an example of the present invention,... Agent:
20150140117 - Bioactivated bone substitute material: The present invention generally relates to the field of bone substitute materials, and particularly to a bone substitute material that is bioactivated. More specifically, the present invention relates to a particular agent comprising citrate, citric acid, monobasic sodium phosphate, dextrose, and adenine for use in improving or promoting osseointegration of... Agent:
20150140118 - Injectable calcium-phosphate cement releasing a bone resorption inhibitor: The present invention relates to a macroporous, resorbable and injectable apatitic calcium-phosphate cement with a high compressive strength useful as bone cement and releasing a bone resorption inhibitor, preparation method and uses thereof.... Agent:
20150140119 - Method for bone tissue regeneration in experiments: The invention relates to the treatment of different bone injuries, particularly fractures and fissure fractures, and can be used in medical and veterinary therapy and surgery. In order to reduce the time taken for bone tissue to regenerate at the site of damage or a defect and to reduce the... Agent:
20150140120 - Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and... Agent: Archemix LLC
20150140121 - Compositions and methods for tight junction modulation: Compositions and methods for modifying the composition of tight junction complexes and/or improving epithelial barrier function are disclosed.... Agent:
20150140124 - Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast... Agent:
20150140122 - Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.... Agent: Inserm (institut National De La Sante Et De La Rec Herche)
20150140123 - Protein expression analyses for identifying genotoxic compounds: The invention relates to a method for screening compounds with (pro-)genotoxic activity by providing a system being capable of expressing a panel of defined proteins, incubating at least a portion of the system with compounds to be screened, and comparing the expression of the proteins in the system with the... Agent:
20150140125 - Synergistic cancer therapy drug combinations: Synergistic cancer therapy drug combinations include therapeutically effective amounts of at least one chemotherapeutic drug or agent with a fortified decoction dosage form comprising from about 10 mg to about 6,000 mg each of β-sitosterol, isovanillin, and linolenic acid. The decoction dosage preferably includes plant extract(s) of the genus Arum... Agent:
20150140126 - Repelling agent, bite repelling agent and arthropod-borne disease preventive agent: A measure that can readily prevent arthropod-borne diseases such as malaria that are contracted by 3 to 5 hundred million people worldwide yearly and that cause death of as many as 1.5 to 2.7 million people. By spraying in advance on the skin an arthropod-borne disease preventive agent or the... Agent: Jichi Medical University
20150140127 - Method for detecting injury to the brain: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination... Agent: Temple University-of The Commonwealth System Of Higher Education
20150140128 - Compositions and methods for the prevention and treatment of cardiovascular diseases: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.... Agent:
20150140129 - Compositions and methods for the prevention and treatment of cardiovascular diseases: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.... Agent:
20150140130 - Treatment of neurological disorders: A treatment of a neurological disorder, including hypoxia, oxygen-glucose deprivation and acute brain trauma in a subject involves administering an effective amount of selenate or a pharmaceutically acceptable salt thereof to the subject. The treatment prevents incurring a symptom, holds in check a symptom or treats an existing symptom of... Agent:
20150140131 - Therapeutic composition and use: The use of liquid formulations in the preparation of a medicament for the prevention and treatment of oral, gastric and digestive infections and in particular for the prevention of ventilator associated pneumonia as well as liquid enteral and parenteral tube feeding compositions. The feeding compositions are suitable for use in... Agent: Queen Mary And Westfield College
20150140133 - In situ controlled release drug delivery system: A system is described for long-term controlled release delivery of a drug or a therapeutic agent. According to the invention, one or more drugs or therapeutic agents contained in microspheres are mixed with a temperature sensitive hydrogel which is then introduced directly to the desired situs of the drug or... Agent:
20150140134 - Natural cream pain reliever: The Natural Cream Pain Reliever is a 100% natural formula with coconut as the main component and a manufacturing process using refrigeration to extract the purist and most concentrated portion of the ingredients.... Agent:
20150140135 - Method of using dietary supplements comprising cinnamon extracts to promote weight loss: A method for promoting weight loss and/or lowering blood glucose comprises an active material which may be cinnamon, an extract of cinnamon, or a derivative of a cinnamon extract. The active material may be utilized in combination with further active ingredients.... Agent: In Ingredients, Inc.
20150140136 - Pesticidal compositions and methods for using same: Pesticidal compositions containing plant essential oils, such as rosemary oil, wintergreen oil, etc., and methods for using same are disclosed.... Agent:
20150140137 - Combined allergy treatment and anti-drying compositions and related methods: Compositions and methods for alleviating an allergy condition while also reducing a drying effect of an allergy treatment composition or another anti-mucosal composition. In some embodiments and implementations, a composition may be provided comprising an allergy treatment composition comprising an antihistamine in a therapeutically effective amount for treating the allergy... Agent:
20150140138 - Decubitus treatment system: The present invention includes compositions and methods for cleaning, treating, protection and resolution of decubitus ulcers comprising: a first composition comprising a wound cleaning solution comprising aloe vera gel comprising at least 5,000 MPS, a balanced salt solution; and a second composition comprising a wound healing gel comprising aloe vera... Agent:
20150140139 - Composition for improving or promoting hair growth containing, as active ingredients, photosensitizer irradiated with light and peptide, and method using same: The present invention relates to a composition for improving or promoting hair growth, which contains, as an active ingredient, a photosensitizer-peptide conjugate, and to a method for screening for the hair growth promoter using the active ingredients. ALA, which is the photosensitizer of the present invention, is preferably activated by... Agent:
20150140140 - Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care: The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-Ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions associated with the skin. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity in... Agent:
20150140141 - Methods for botanical and/or algae extraction: The present disclosure relates to methods for extraction of biomass. Biomass of most interest is that which contains biologically active, extracts suitable for the skin care market. The biomass of interest includes botanicals (plant extracts and bioferments thereof), algae (red, brown, green and red, including bioferments thereof), fungi and even... Agent: Basf Corporation
20150140142 - Medicinal composition of extract of seed of emblica officinalis and method of preparing the same: A composition having an extract of seed of Emblica officinalis. Methods of preparing extract of seed of Emblica officinalis. An amla seed blend composition having various ratios of extracts of seeds of Emblica officinalis. Nutraceutical or pharmaceutical methods for decreasing the total cholesterol, decreasing triglyceride, decreasing blood glucose level, enhancing... Agent:
20150140143 - Nutriprotective diet: The present document describes a nutriprotective diet comprising a nutriprotective amount of a sugar plant syrup, a sugar plant syrup extract, a sugar plant extract, or combinations thereof The present document also describes a method of eliciting a nutriprotective effect in a subject, which comprises administering a nutriprotective amount of... Agent: FÉ DÉ Ration Des Producteurs AcÉ Ricoles Du QuÉ Bec
20150140144 - Aqueous-lipidic carotenoid-containing compositions: The invention provides a primary carotenoid-containing composition comprising an aqua-containing component, a lipid-containing component and a carotenoid-containing fiber material from plant origin with lowered content of aqua-soluble substances. The invention also provides oral compositions that comprise the primary composition in a foodstuff, in a food supplement or in a pharmaceutical... Agent:Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20150521:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.